AWH — Aspira Women's Health Inc.

Summary of AWH Q3 2024 Earnings Call

1. Key Financial Results and Metrics:

• OvaSuite Revenue: $2.3 million, a 2% increase year-over-year but a slight decrease from $2.4 million in Q2 2024.
• OvaSuite Tests Performed: Over 6,000 tests, a 4% increase from approximately 5,783 tests in Q3 2023.
• Average Unit Price (AUP): $376, down from $383 in Q3 2023; OvaWatch AUP increased to $360 from $347.
• Gross Margin: Improved to 60% from 59% year-over-year.
• R&D Expenses: Decreased by 9% to $900,000 due to deferred spending; expected to rise in Q4 2024.
• Sales and Marketing Expenses: Increased by 26% to $2.1 million due to hiring and website launch costs.
• General and Administrative Expenses: Decreased by 25% to $2 million, attributed to reduced personnel and legal fees.
• Cash Used in Operating Activities: $2.9 million, down 12% from Q3 2023; cash and restricted cash totaled $2.1 million as of September 30, 2024.
• Guidance: Reiterated cash used in operations for 2024 to be less than $14.5 million.

2. Strategic Updates and Business Highlights:

• OvaWatch Launch: Significant growth with a 27% year-over-year increase in test volume, now comprising 22% of total OvaSuite volume.
• New Partnership with Dorsata: Aimed at integrating clinical decision-making tools into EMR systems to enhance OvaSuite adoption.
• OvaWatch Approval: Received approval from New York State, expanding access to a major healthcare market.
• Federal Award for ENDOinform: Secured a $10 million grant from ARPA-H to develop a multi-omic blood test for endometriosis, with significant progress on clinical studies.

3. Forward Guidance and Outlook:

• Anticipates reordering behavior for OvaSuite tests to change as providers begin retesting patients in 2025.
• Plans to leverage the ARPA-H award for increased visibility and market presence, including a redesigned website and social media strategy.
• ENDOinform development is expected to progress rapidly, with the goal of launching within the two-year funding period.

4. Bad News, Challenges, or Points of Concern:

• Impact of Severe Weather: Hurricane Helene negatively affected test volume in key markets, contributing to moderated growth.
• Cash Position: Decrease in cash and restricted cash from $2.9 million at year-end 2023 to $2.1 million, raising concerns about liquidity.
• Complex Accounting Issues: Extension filed for Form 10-Q due to complex accounting related to a warrants inducement transaction, which could delay financial reporting.

5. Notable Q&A Insights:

• Timeline for ENDOinform Development: While the full two years of funding from ARPA-H is contracted, there is optimism for acceleration in development.
• Partnership Opportunities: Future partnerships with companies developing endometriosis therapies are anticipated, contingent on successful commercialization of ENDOinform.
• Positive Partnership Environment: There is a hopeful outlook for increased investment in women's health, which may enhance collaboration opportunities.

Overall, Aspira Women's Health demonstrated modest growth in Q3 2024 despite challenges from external factors, while making significant strides in product development and strategic partnerships. The company remains focused on innovation and improving health outcomes for women.